Objective: To examine the dose-response effects of aerobic exercise on health-related quality of life (HRQoL) among colon cancer survivors.
| BACKGROUND
Approximately 1 million people are diagnosed with colon cancer each year worldwide. 1 As a result of earlier detection and more efficacious therapies, mortality from colon cancer has decreased over the past 50 years. 2 The long-term survival rate of colon cancer survivors who remain in remission is similar to the general population. 3 Despite improvements in survival, colon cancer survivors often report impairments in multiple dimensions of health-related quality of life (HRQoL)
when compared with the general population. These impairments include inferior physical and mental wellness, higher rates of insomnia, persistent cancer-related fatigue, and impairments specific to colon cancer, such as anxiety about disease recurrence and bowel dysfunction. [4] [5] [6] [7] [8] [9] Among colon cancer survivors, physical activity volume declines during cancer therapy and often does not return to pre-diagnosis volumes after completing therapy. 10, 11 This may explain, in part, why up to 90% of colon cancer survivors do not engage in the recommended minimum volume of 150 min·wk −1 of physical activity. 12 Cross-sectional studies demonstrate that larger volumes of physical activity are correlated with higher physical and mental wellness, better sleep quality, lower fatigue, less worry about disease recurrence, and better bowel function. [13] [14] [15] [16] [17] Prospective cohort studies demonstrate that increases in physical activity volume are correlated with improvements in HRQoL. [18] [19] [20] [21] However, randomized trials have failed to demonstrate that exercise improves HRQoL among colon cancer survivors. 22 For example, 102 colon cancer survivors randomized to a 16-week moderate-intensity aerobic exercise program did not significantly improve
HRQoL compared with a usual-care control group. 23 In another study, 46 colon cancer survivors randomized to a 12-week home-based aerobic walking program with behavioral counseling did not improve
HRQoL compared with a control group who received weekly telephone contact. 24 These randomized trials have prescribed volumes of exercise that range from 60 to 150 min·wk
. 22 Larger volumes of exercise, such as 300 min·wk −1 , are associated with a lower risk of disease recurrence and premature mortality in colon cancer survivors. 25 It is plausible that a larger volume of exercise, such as 300 min·wk −1 , may also be necessary to promote improvements in HRQoL among colon cancer survivors. 26 The COURAGE trial was a randomized controlled trial with the primary aim to examine the safety, feasibility, and biological efficacy of 150 and 300 min·wk −1 of aerobic exercise versus usual-care control over 6 months among men and women with a history of stage I to III colon cancer. 27 The primary and secondary biologic outcomes of the COURAGE trial have been published. [28] [29] [30] Patient-reported HRQoL outcomes were pre-specified as secondary study outcomes. Our hypothesis was that exercise would improve HRQoL outcomes in a dose-response fashion, such that high-dose aerobic exercise would yield the largest improvements in HRQoL outcomes.
| METHODS

| Study design and participants
The COURAGE trial was a single-center, phase II, randomized, 3-arm dose-response exercise trial. 27 Inclusion and exclusion criteria are presented in Table 1 
| Randomization and masking
Using a computer-generated randomization algorithm (ralloc procedure in Stata), participants were randomly allocated to 1 of 3 groups: 
| Exercise treatment plan
Aerobic exercise was performed over 6 months using study-provided in-home treadmills (LifeSpan Fitness, TR1200i, Salt Lake City, UT).
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Participants were provided with a heart rate monitor to objectively record heart rate during each exercise session. Using a combination of in-person, telephone, and email communication, the exercise physiologist provided ongoing behavioral and clinical support and monitored exercise adherence to the study protocol throughout the duration of the study. Behavioral support was individualized to each participant to include the benefits of exercise for colon cancer survivors, strategies to integrate exercise into day-to-day activities, how to identify and overcome barriers to exercise, recruiting friends and family members to provide support in reaching their exercise goals, and how to set simple, measurable, attainable, realistic, and timely goals to promote exercise self-efficacy and compliance. 27 Exercise intensity was prescribed at 50% to 70% of the age-predicted maximum heart rate (equivalent to 3-6 METs 32 ) using heart rate monitors. The low-dose and high-dose groups progressed towards of the goal of 150 or 300 min·wk −1 of exercise, respectively. Exercise adherence was calculated using the completed number of minutes divided by the prescribed number of minutes, with a maximum value of 100%.
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Participants randomized into the usual-care control group were asked to maintain their pre-study levels of physical activity and/or follow the recommendations provided by their physician. After completing 6-month measures, control group participants were provided with an in-home treadmill and individualized exercise program, like that of the 2 exercise groups. Upon study completion, all participants could keep their study-provided treadmills.
| Measurements
Demographic characteristics including age, sex, race, education, occupation, and marital status were self-reported. Smoking status and alcohol consumption were obtained from standardized questionnaires developed by the National Center for Health Statistics. 33 Clinical information including cancer stage and treatment with chemotherapy were obtained from cancer registry, pathology reports, or physician records.
| Study outcomes
HRQoL outcomes were assessed at baseline and 6 months. Physical and mental wellness was quantified using the Medical Outcomes Sur- respectively. 41 To evaluate the presence of a dose-response relationship across randomized groups, a test of trend was conducted by examining linear contrasts. We did not adjust our type I error rate, and the results should be interpreted accordingly.
| RESULTS
Between January 2015 and August 2015, 39 colon cancer survivors were recruited and randomized with endpoint data collection ending in February 2016. Baseline characteristics of study participants are presented in Table 2 . Over 6 months, adherence to the prescribed volumes of exercise in the low-dose and high-dose groups were 93 ± 2% and 89 ± 3%, respectively. Average exercise volume of the low-dose and high-dose groups were 141 ± 10 min·wk −1 and 247 ± 11 min·wk , respectively (Δ between groups: 106 ± 15; P < 0.001).
HRQoL outcomes are presented in Table 3 . At baseline, no statistically significant differences in HRQoL outcomes were observed among the 3 groups. Compared with the control group, over 6 months, the SF-36 physical health component summary score increased by
1.2 ± 6.3 (d = 0.08) in the low-dose group and 13.1 ± 6.5 (d = 0.58) in the high-dose group (P trend = 0.002). No change was observed in the SF-36 mental health component summary score. SF-36 subscales that demonstrated significant improvements included physical functioning (P trend < 0.001), role-physical (P trend = 0.035), general health (P trend = 0.011), and vitality (P trend = 0.025; Supplementary Table 1) .
Compared with the control group, over 6 months, the FACT-C score increased by 7.6 ± 3. 
| Clinical implications
An improvement of approximately one-half of a standard deviation (d = 0.5) is considered a minimally clinically important difference for patient-reported HRQoL measures. 42 Therefore, the magnitude of Test for trend P = 0.369
Abbreviations: LS Mean, least-squares mean; SD, standard deviation; SE, standard error.
Changes in outcomes are estimated using a linear mixed-effects regression model that adjusted for the baseline value of the dependent variable and cancer stage (randomization stratification factor).
improvement for several outcomes in this study, including the SF-36 physical subscale, FACT-C, and FSI, are consistent with a clinically meaningful benefit. The findings from this trial contrast with prior ran- have reported control group crossover (eg, control group participants engaging in exercise) due to the inability to blind participants to their assigned intervention, 23 resulting in an attenuation of the exerciseinduced HRQoL effects. In our study, mean objectively measured exercise adherence was below prescribed levels in both arms of the trial (93 ± 2% in low-dose and 89 ± 3% in high-dose), but the completed exercise volumes were likely higher than prior trials. Third, it has been noted that younger colon cancer survivors (<60 years) may be particularly prone to impairments in HRQoL and are often motivated to engage in healthy risk-reducing behaviors. 4, 7, 43 Our study sample was significantly younger than the population-based registry from which they were recruited, 27 and 64% of our sample was <60 years. Our study sample was younger than some, 23, 44 but not all prior studies. 24 Fourth, over 6 months, the control group in our trial reported deteriorations in several HRQoL outcomes including the SF-36 physical health component summary score and the FACT-C. Such deteriorations have not been observed in prior studies of colon cancer survivors. 23, 24, 44 The reasons for the observed deteriorations among participants in the control group are not clear. In this situation, exercise may help to prevent the deterioration of HRQoL. 45 The ability to rapidly implement these findings into clinical practice may be challenging. The majority of colon cancer survivors do not engage in adequate physical activity. 12 Our study population was motivated to enroll into a clinical trial, was provided with an in-home treadmill, and received individualized behavioral support to promote adherence to the study protocol. Given the benefits of exercise and lifestyle modification, further research is necessary to understand how to disseminate efficacious behavioral interventions into the oncology clinic.
Contrary to our hypothesis, we did not observe significant doseresponse reductions in the FCRI. Colon cancer survivors rank fear of disease recurrence as their primary health concern. 46 Low-level risk perceptions, worry, and anxiety about disease recurrence are common in this population. 7 In a cross-sectional study of 10 969 colorectal cancer survivors, higher volumes of physical activity were associated with a significantly lower fear of disease recurrence in a linear dose-response fashion. 13 Although we did not observe a statistically significant doseresponse effect on the FCRI summary score, the high-dose group reported significant improvements on the FCRI subscales including psychological distress (P = 0.009), functional impairment (P = 0.005), insight (P = 0.006), reassurance (P < 0.001), and coping (P = 0.047), whereas no significant changes were observed in the control or low-dose groups.
These findings provide preliminary data to justify additional research to examine the potential role of exercise to manage or mitigate concerns regarding disease recurrence in this population.
There are several strengths to this study. The randomized design that included the use of 2 distinct exercise doses allowed us to understand how HRQoL outcomes change along the exercise dose curve.
Both exercise groups had excellent adherence (~90%). Follow-up was robust, with only 1 participant being lost to follow-up (97% completion rate). Despite the small sample size, 21% of study participants reported being non-white race. Our HRQoL outcomes included a variety of validated, well-characterized HRQoL questionnaires.
| Study limitations
There are several limitations to this study. The small sample size likely limited our statistical power to detect significant changes in the mental health component score of the SF-36 and bowel function questionnaires. The small sample size allowed for numeric, but non-statistically significant, differences in baseline HRQoL values. We expected this may occur, and our analysis plan pre-specified that the baseline value of the dependent variable would be included in the model to account for baseline differences; however, we cannot rule out the possibility that the observed differences may be partly due to regression to the mean. The small sample size also reduces the generalizability of our findings and precluded our ability to conduct subgroup analysis to identify factors that may moderate the relationship between exercise dose and HRQoL outcomes (such as age). We did not recruit study participants based on having poor HRQoL at baseline. Although we identified statistically significant dose-response patterns across randomized group for several HRQoL outcomes, the benefit was often small or modest in effect size. It is unknown if exercise would yield the same magnitude of benefit among individuals with poor HRQoL at baseline. It is plausible that such participants may derive larger benefits from exercise. However, the converse is also possible, such that high volumes of exercise may not be feasible for participants with poor HRQoL, such as poor physical functioning or severe cancerrelated fatigue. Study participants were not blinded to treatment group assignment. Therefore, social desirability bias cannot be excluded, which may overestimate the efficacy of exercise on these outcomes.
We did not adjust our type I error rate; thus, the possibility of falsepositive findings cannot be ruled out.
| CONCLUSION
In conclusion, the findings from this randomized trial demonstrate the dose-response effects of moderate-intensity aerobic exercise to improve multiple HRQoL outcomes and suggest that a high-dose of aerobic exercise (300 min·wk ) may be needed to improve physical function, cancer-specific quality of life, sleep quality, and fatigue among early-stage colon cancer survivors. These findings suggest that higher volumes of aerobic exercise are necessary to improve HRQoL outcomes in colon cancer survivors.
